Study on the Use of Micropulse Laser to Treat Central Serous Chorioretinopathy

Study Overview
=================
Brief Summary
-----------------
The investigators hypothesis is that using the micropulse laser in patient with Central Serous Chorioretinopathy (CSC) will prompt resolution of CSC and will be effective in significantly minimizing visual recovery time from this disease as well as potentially preventing recurrences.

Detailed Description
-----------------
The investigators hypothesize that application of 577nm micropulse laser in patients with CSC will prompt resolution of CSC as measured by ocular coherence tomography and best corrected visual acuity. This will be a pilot study to establish sound methods and provide some insights to the safety and efficacy of CSC treatment.

Official Title
-----------------
A Prospective Study of the Use of Micropulse 577nm Laser Treatment in Central Serous Chorioretinopathy

Conditions
-----------------
Central Serous Chorioretinopathy

Intervention / Treatment
-----------------
* Device: Micropulse Laser Treatment
* Other: No treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with new diagnosis of CSC and no other comorbidities or prior retinal treatment Patients ranging from 30 to 60 years of age Exclusion Criteria: Patients with no case of CSC Patients with other macular comorbidities including but not limited to diabetic retinopathy, macular degeneration Patients with prior retinal treatment

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Micropulse Laser Treatment<br>Patient's randomized to ML treatment would be treated with the following settings: 200 micron spot size, 0.2 second duration, 15% duty cycle, and 300 milliWatt power. Their eyes would be dilated prior to treatment with standard mydriatic medications, including Tropicamide and Phenylephrine | Device: Micropulse Laser Treatment<br> <br> * Other names: Laser;|
| Placebo Comparator: No Treatment<br>Patients randomized to this treatment arm, will not receive treatment for CSC. They will continue to be observed at month 1 and month 3. If any worsening of pathology is found during the follow up visits, the patient will be removed from the study and given appropriate standard of care by the attending | Other: No treatment<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Resolution of Fluid Build-up | Central Serous Choroidopathy is a disease that causes fluid to build up under the retina,the back part of the inner eye that sends sight information to the brain. The objective here is to apply 577nm of micropulse laser to see if CSC resolution occurs and measuring it through ocular coherence tomography (retinal imaging), vision score, and visual field testing for retinal sensitivity. | within 1 week to 3 months after the laser procedure is completed | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CSC, Edema, Retinopathy